Study in Healthy Subjects to Investigate the Relative Bioavailability and Safety of Pasireotide After Single Subcutaneous Dose Administration Using a Reusable ServoPen With Cartridge as Compared to Administration Using a Syringe Drawn From an Ampule

This single-center Phase 1 study in healthy male and female subjects of 18 to 55 years (inclusive) will follow an open-label, randomized, single-dose, crossover design with 2 intervention periods. The purpose of this study is to assess and compare the pharmacokinetic characteristics and the safety of single doses of pasireotide when administered subcutaneously by reusable ServoPen with cartridge or by syringe drawn from an ampule in healthy subjects.

NCT Number	NCT07312643
Lead Sponsor	RECORDATI GROUP Collaborators: Nuvisan
Conditions	Pharmacokinetics, Safety
Enrollment	40 participants
Start Date	2025-12-01
Primary Completion	2026-02-03 (estimated)
Study Completion	2026-02-03 (estimated)
Updated on ClinicalTrials.gov	2026-02-04